MA29879B1 - Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih - Google Patents

Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih

Info

Publication number
MA29879B1
MA29879B1 MA30862A MA30862A MA29879B1 MA 29879 B1 MA29879 B1 MA 29879B1 MA 30862 A MA30862 A MA 30862A MA 30862 A MA30862 A MA 30862A MA 29879 B1 MA29879 B1 MA 29879B1
Authority
MA
Morocco
Prior art keywords
optionally substituted
lower alkyl
substituted lower
heterocycle
hydrogen
Prior art date
Application number
MA30862A
Other languages
English (en)
Inventor
Hiroshi Yoshida
Takashi Kawasuji
Teruhiko Taishi
Yoshiyuki Taoda
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37967785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29879(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MA29879B1 publication Critical patent/MA29879B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Consiste à proposer un nouveau composé ayant une activité anti-virale, particulièrement une activité inhibitrice de l'intégrase du VIH, et une composition pharmaceutique, particulièrement un agent anti-VIH. (dans laquelle R1 est un hydrogène ou un alkyle inférieur ; X est un alkylène inférieur, etc. : R2 est un aryle facultativement substitué ; R3 est un hydrogène, un halogène, un hydroxy, un alkyle inférieur facultativement substitué, etc. : R4 est un hydrogène, un alkyle inférieur facultativement substitué, un cycloalkyle facultativement substitué, un cycloalkyle alkyle inférieur facultativement substitué, un aryle facultativement substitué, un aryle alkyle inférieur facultativement substitué, un groupement hétérocyclique facultativement substitué, un hétérocycle alkyle inférieur facultativement substitué, etc. : Une ligne de tirets indique la présence ou l'absence d'une liaison ; B1 et B2 sont tels que l'un quelconque d'entre eux est un CR20R21, et l'autre est un NR22 et, dans ce cas, il n'y a pas de ligne de tirets. Quand B2 est un NR22, R4 et R22 peuvent être pris ensemble pour former un hétérocycle facultativement substitué ; Quand B2 est CHR21, R4 et R21 peuvent être pris ensemble pour former un hétérocycle facultativement substitué. À titre d'alternative, B1 et B2 sont indépendamment un C, un CR23 ou un N et, dans ce cas, B1 et B2 peuvent être pris ensemble pour former un hétérocycle. R20, R21, R22 et R23 sont indépendamment un hydrogène, un alkyle inférieur facultativement substitué, un cycloalkyle facultativement substitué, un cycloalkyle alkyle inférieur facultativement substitué, etc.)
MA30862A 2005-10-27 2008-04-23 Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih MA29879B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005312076 2005-10-27
JP2006223875 2006-08-21

Publications (1)

Publication Number Publication Date
MA29879B1 true MA29879B1 (fr) 2008-10-03

Family

ID=37967785

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30862A MA29879B1 (fr) 2005-10-27 2008-04-23 Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih

Country Status (15)

Country Link
US (2) US8188271B2 (fr)
EP (1) EP1950212B1 (fr)
JP (1) JP5131689B2 (fr)
KR (1) KR20080064182A (fr)
AU (1) AU2006307101A1 (fr)
BR (1) BRPI0617842A2 (fr)
CA (1) CA2626956A1 (fr)
EA (1) EA200801144A1 (fr)
ES (1) ES2569357T3 (fr)
IL (1) IL190879A0 (fr)
MA (1) MA29879B1 (fr)
MX (1) MX2008005137A (fr)
NO (1) NO20081892L (fr)
TW (1) TW200800988A (fr)
WO (1) WO2007049675A1 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101363875B1 (ko) 2005-04-28 2014-02-21 시오노기세야쿠 가부시키가이샤 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체
MX2008005137A (es) 2005-10-27 2008-09-29 Shionogi & Co Derivado de carbamoilpiridona policiclica que tiene actividad inhibidora en vih integrasa.
US7482345B2 (en) * 2005-12-05 2009-01-27 Meng-Hsin Chen P38 kinase inhibiting agents
ATE541841T1 (de) 2007-11-15 2012-02-15 Boehringer Ingelheim Int Inhibitoren der replikation des human immunodeficiency virus
ES2402322T3 (es) * 2007-11-15 2013-04-30 Gilead Sciences, Inc. Inhibidores de la replicación del virus de la inmunodeficiencia humana
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
WO2010011814A1 (fr) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Composés chimiques
CN102245572B (zh) 2008-12-11 2015-03-25 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
KR101733625B1 (ko) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8927710B2 (en) * 2009-06-15 2015-01-06 Shionogi & Co., Ltd. Substituted polycyclic carbamoylpyridone derivative
ES2446720T3 (es) * 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
CA2789457A1 (fr) 2010-02-26 2011-09-01 Susumu Miyazaki Derive de 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine et son utilisation comme inhibiteur d'integrase de vih
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
US9216995B2 (en) * 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
DK2620436T3 (en) * 2010-09-24 2018-07-30 Shionogi & Co Substituted polycyclic carbamoylpyridone derivative prodrug
RU2014113230A (ru) * 2011-10-12 2015-11-20 Шионоги Энд Ко., Лтд. Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013102142A1 (fr) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Composés benzaldéhyde substitués et procédés d'utilisation de ceux-ci dans l'augmentation de l'oxygénation des tissus
EP2931730B1 (fr) * 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. Dérivés 4-pyridinonetriazines en tant qu'inhibiteurs de l'intégrase du vih
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
PE20151063A1 (es) 2012-12-27 2015-08-03 Japan Tobacco Inc DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP3919056B1 (fr) 2013-03-15 2024-08-28 Global Blood Therapeutics, Inc. Composés et leurs utilisations pour la modulation de l'hémoglobine
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (fr) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Composés aldéhydes substitués et leurs procédés d'utilisation pour accroître l'oxygénation tissulaire
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP3008044B1 (fr) * 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (fr) 2013-07-12 2018-07-21
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015089847A1 (fr) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih
ES2860648T5 (es) 2014-02-07 2024-11-27 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (fr) 2014-06-20 2018-06-23
JPWO2016027879A1 (ja) 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
SG11201708721XA (en) 2015-04-28 2017-11-29 Shionogi & Co Substituted polycyclic pyridone derivative and prodrug thereof
WO2016187788A1 (fr) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles pour traiter l'infection au vih
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201804348SA (en) 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
KR20190018469A (ko) 2016-08-10 2019-02-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CA3042314A1 (fr) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Composes heterocycliques tricycliques utiles en tant qu'inhibiteurs de l'integrase du vih
JP7027179B2 (ja) * 2018-01-24 2022-03-01 キヤノン株式会社 給送回転体、シート給送装置及び画像形成装置
EP3752144B1 (fr) * 2018-02-15 2022-12-28 Merck Sharp & Dohme LLC Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
EP4257137A3 (fr) * 2018-05-31 2023-11-01 Shionogi & Co., Ltd Dérivés de carbamoylpyridone polycycliques pour le traitement du vih
MA52802A (fr) * 2018-05-31 2021-04-14 Shionogi & Co Dérivé de pyridone polycyclique
TWI820141B (zh) * 2018-05-31 2023-11-01 日商鹽野義製藥股份有限公司 衍生物
JP7307412B2 (ja) * 2018-06-27 2023-07-12 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
CA3112326A1 (fr) * 2018-09-12 2020-03-19 Novartis Ag Composes antiviraux de pyridopyrazinedione
EP3860975B1 (fr) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
WO2021107065A1 (fr) * 2019-11-28 2021-06-03 塩野義製薬株式会社 Dérivé de pyridopyrazine polycyclique
EP4066839A4 (fr) * 2019-11-28 2023-12-27 Shionogi & Co., Ltd Agent pharmaceutique prophylactique et thérapeutique pour maladies infectieuses à vih, caractérisé en ce qu'il comprend une combinaison d'un inhibiteur d'intégrase et d'un agent anti-vih
JP7361013B2 (ja) * 2019-11-28 2023-10-13 塩野義製薬株式会社 多環性カルバモイルピリドン誘導体を含有する医薬組成物
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
US20240018145A1 (en) * 2020-07-27 2024-01-18 Merck Sharp & Dohme Llc Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza
ES3064867T3 (en) 2020-09-30 2026-04-29 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
PL360944A1 (en) * 2000-10-12 2004-09-20 Merck & Co, Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
ES2572030T3 (es) 2001-08-10 2017-07-19 Shionogi & Co., Ltd. Agente antiviral
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7300364B2 (en) 2004-02-06 2007-11-27 Acushnet Company Multi-layer golf ball having velocity gradient from faster center to slower cover
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
ATE404537T1 (de) 2002-08-13 2008-08-15 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
CA2498111A1 (fr) 2002-09-11 2004-03-25 Merck & Co., Inc. Composes de dihydroxypyridopyrazine-1,6-diones utiles en tant qu'inhibiteurs de l'integrase du vih
NZ540729A (en) * 2002-12-27 2008-03-28 Angeletti P Ist Richerche Bio Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US20070161639A1 (en) * 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
WO2006066414A1 (fr) * 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones et procedes d’inhibition de l’integrase du vih
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
KR101363875B1 (ko) 2005-04-28 2014-02-21 시오노기세야쿠 가부시키가이샤 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
MX2008005137A (es) 2005-10-27 2008-09-29 Shionogi & Co Derivado de carbamoilpiridona policiclica que tiene actividad inhibidora en vih integrasa.

Also Published As

Publication number Publication date
JP5131689B2 (ja) 2013-01-30
US20120208998A1 (en) 2012-08-16
BRPI0617842A2 (pt) 2011-08-09
EP1950212A4 (fr) 2010-08-04
EP1950212A1 (fr) 2008-07-30
NO20081892L (no) 2008-06-23
US8188271B2 (en) 2012-05-29
EA200801144A1 (ru) 2008-10-30
CA2626956A1 (fr) 2007-05-03
US20090143356A1 (en) 2009-06-04
ES2569357T3 (es) 2016-05-10
KR20080064182A (ko) 2008-07-08
TW200800988A (en) 2008-01-01
JPWO2007049675A1 (ja) 2009-04-30
MX2008005137A (es) 2008-09-29
IL190879A0 (en) 2008-11-03
EP1950212B1 (fr) 2016-02-24
AU2006307101A1 (en) 2007-05-03
WO2007049675A1 (fr) 2007-05-03

Similar Documents

Publication Publication Date Title
MA29879B1 (fr) Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih
Montoya et al. Antifungal phenothiazines: optimization, characterization of mechanism, and modulation of neuroreceptor activity
Taha et al. Synthesis and evaluation of unsymmetrical heterocyclic thioureas as potent β-glucuronidase inhibitors
TR199701194T1 (xx) Aspartil proteaz�n oksijenlenmi� heterosikl i�eren s�lfonamit inhibit�rleri.
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
ATE288681T1 (de) Fungizide verbindungen
TR199701199T1 (xx) Aspartil proteaz�n THF i�eren s�lfonamit inhibit�rleri.
ATE242783T1 (de) Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
BR9814340A (pt) Derivados de indol como inibidores de fator xa
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
CY1111816T1 (el) Παραγωγο θειαδιαζολινης για την θεραπεια του καρκινου
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
BR0211427A (pt) Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos
KR960006915A (ko) 췌장염의 치료 조성물
KR910004191A (ko) 신질환치료제
BR0308588A (pt) Inibidores de entrada de molécula pequena
Sharma et al. 5‐Arylidene‐2, 4‐thiazolidinediones as Cysteine Protease Inhibitors against Leishmania donovani
EP1404652A4 (fr) Nouveau derive alcaloide et composition pharmaceutique le contenant
Cihan‑Üstündağ et al. Synthesis of New N‐(3‐oxo‐1‐thia‐4‐azaspiro [4.5] decan‐4‐yl) pyridine‐3‐carboxamide Derivatives and Evaluation of Their Anti‐Influenza Virus and Antitubercular Activities
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
MA27963A1 (fr) Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
BRPI0401949A (pt) Compostos de benzotiazina e benzotiadiazina, processo para sua preparação e composições farmacêuticas que contém esses compostos
BR0314714A (pt) Compostos para o tratamento da doença de alzheimer
Caba-Flores et al. Activity in vitro of 2-chloro-N-[4-(4-chlorophenyl)-2-thiazolyl] acetamide against promastigotes of Leishmania mexicana: an apoptosis inducer